Researchers reported that longitudinal plasma proteomics can identify markers that predict phenoconversion to clinically manifest ALS. In Nature Medicine, investigators analyzed data from the NIH-funded Pre-symptomatic Familial ALS (Pre-fALS) cohort and identified a panel of proteins whose changes preceded the onset of symptoms. The work used repeated blood sampling over time and emphasized that the biomarker panel improved timing estimates for when carriers would become symptomatic—reducing uncertainty compared with prior approaches. The authors also discussed earlier signals such as neurofilament light chain, while positioning the new protein lineup as an expanded trajectory map. For translational teams, the study provides a measurable route toward prevention-style trial design in genetic ALS, where accurate enrollment timing and outcome windows are central operational bottlenecks.